Emerging and clinical-stage biotech: financings, readouts, regulatory milestones and C-suite moves.
Every story from The Biotech Brief, newest first.
Fresh off selling Vega to Incyte and floating Electra, the team is restarting with a preclinical hematology and immunology pipeline. Janus Henderson says it rarely invests this early.
Read the full story →Non-dilutive money for the Phase 1/2 trial of EPI-321, a one-time epigenetic therapy that silences DUX4 in FSHD without cutting DNA.
Read the full story →ARD-101 for Prader-Willi hunger can return to the clinic once a new Phase 3 design is agreed, after a fresh ECG study found no cardiac events.
Read the full story →Its bioengineered Inspirex Lung aims to rescue injured donor lungs. The grant funds first-in-human studies.
Read the full story →The pancreatic cancer ADC now has orphan status, an active IND and Fast Track, all before its first Phase 1 patient.
Read the full story →Jordan Griffiths specialises in Biotech, R&D & Clinical hiring at QP Group. Talk to Jordan about the market, salaries or a search.
The full archive of The Biotech Brief.
A three-minute weekly read: funding, launches, leadership moves and what they mean for hiring. Written by Jordan Griffiths. No spam, one-click unsubscribe.
